Cargando…

Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer

BACKGROUND: Epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSC) contribute to tumour progression and metastasis. Assessment of transcription factors involved in these two mechanisms can help to identify new targets for an oncological therapy. In this study, we focused on the evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerbs, Tristan, Bisht, Savita, Schölch, Sebastian, Pecqueux, Mathieu, Kristiansen, Glen, Schneider, Martin, Hofmann, Bianca T., Welsch, Thilo, Reissfelder, Christoph, Rahbari, Nuh N., Fritzmann, Johannes, Brossart, Peter, Weitz, Jürgen, Feldmann, Georg, Kahlert, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383957/
https://www.ncbi.nlm.nih.gov/pubmed/28388884
http://dx.doi.org/10.1186/s12885-017-3225-5
_version_ 1782520377656737792
author Lerbs, Tristan
Bisht, Savita
Schölch, Sebastian
Pecqueux, Mathieu
Kristiansen, Glen
Schneider, Martin
Hofmann, Bianca T.
Welsch, Thilo
Reissfelder, Christoph
Rahbari, Nuh N.
Fritzmann, Johannes
Brossart, Peter
Weitz, Jürgen
Feldmann, Georg
Kahlert, Christoph
author_facet Lerbs, Tristan
Bisht, Savita
Schölch, Sebastian
Pecqueux, Mathieu
Kristiansen, Glen
Schneider, Martin
Hofmann, Bianca T.
Welsch, Thilo
Reissfelder, Christoph
Rahbari, Nuh N.
Fritzmann, Johannes
Brossart, Peter
Weitz, Jürgen
Feldmann, Georg
Kahlert, Christoph
author_sort Lerbs, Tristan
collection PubMed
description BACKGROUND: Epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSC) contribute to tumour progression and metastasis. Assessment of transcription factors involved in these two mechanisms can help to identify new targets for an oncological therapy. In this study, we focused on the evaluation of the transcription factor Six1 (Sine oculis 1). This protein is involved in embryologic development and its contribution to carcinogenesis has been described in several studies. METHODS: Immunohistochemistry against Six1 was performed on a tissue microarray containing specimens of primary pancreatic ductal adenocarcinomas (PDAC) of 139 patients. Nuclear and cytoplasmic expression was evaluated and correlated to histopathological parameters. Expression of Six1 was inhibited transiently by siRNA in Panc1 and BxPc3 cells and stably by shRNA in Panc1 cells. Expression analysis of CDH1 and Vimentin mRNA was performed and cell motility was tested in a migration assay. Panc1 cells transfected with Six1 shRNA or scrambled shRNA were injected subcutaneously into nude mice. Tumour growth was observed for four weeks. Afterwards, tumours were stained against Six1, CD24 and CD44. RESULTS: Six1 was overexpressed in the cytoplasm and cellular nuclei in malignant tissues (p < 0.0001). No correlation to histopathological parameters could be detected. Six1 down-regulation decreased pancreatic cancer cell motility in vitro. CDH1 and vimentin expression was decreased after inhibition of the expression of Six1. Pancreatic tumours with impaired expression of Six1 showed significantly delayed growth and displayed loss of the CD24(+)/CD44(+) phenotype. CONCLUSION: We show that Six1 is overexpressed in human PDAC and that its inhibition results in a decreased tumour progression in vitro and in vivo. Therefore, targeting Six1 might be a novel therapeutic approach in patients with pancreatic cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3225-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5383957
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53839572017-04-10 Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer Lerbs, Tristan Bisht, Savita Schölch, Sebastian Pecqueux, Mathieu Kristiansen, Glen Schneider, Martin Hofmann, Bianca T. Welsch, Thilo Reissfelder, Christoph Rahbari, Nuh N. Fritzmann, Johannes Brossart, Peter Weitz, Jürgen Feldmann, Georg Kahlert, Christoph BMC Cancer Research Article BACKGROUND: Epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSC) contribute to tumour progression and metastasis. Assessment of transcription factors involved in these two mechanisms can help to identify new targets for an oncological therapy. In this study, we focused on the evaluation of the transcription factor Six1 (Sine oculis 1). This protein is involved in embryologic development and its contribution to carcinogenesis has been described in several studies. METHODS: Immunohistochemistry against Six1 was performed on a tissue microarray containing specimens of primary pancreatic ductal adenocarcinomas (PDAC) of 139 patients. Nuclear and cytoplasmic expression was evaluated and correlated to histopathological parameters. Expression of Six1 was inhibited transiently by siRNA in Panc1 and BxPc3 cells and stably by shRNA in Panc1 cells. Expression analysis of CDH1 and Vimentin mRNA was performed and cell motility was tested in a migration assay. Panc1 cells transfected with Six1 shRNA or scrambled shRNA were injected subcutaneously into nude mice. Tumour growth was observed for four weeks. Afterwards, tumours were stained against Six1, CD24 and CD44. RESULTS: Six1 was overexpressed in the cytoplasm and cellular nuclei in malignant tissues (p < 0.0001). No correlation to histopathological parameters could be detected. Six1 down-regulation decreased pancreatic cancer cell motility in vitro. CDH1 and vimentin expression was decreased after inhibition of the expression of Six1. Pancreatic tumours with impaired expression of Six1 showed significantly delayed growth and displayed loss of the CD24(+)/CD44(+) phenotype. CONCLUSION: We show that Six1 is overexpressed in human PDAC and that its inhibition results in a decreased tumour progression in vitro and in vivo. Therefore, targeting Six1 might be a novel therapeutic approach in patients with pancreatic cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3225-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-07 /pmc/articles/PMC5383957/ /pubmed/28388884 http://dx.doi.org/10.1186/s12885-017-3225-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lerbs, Tristan
Bisht, Savita
Schölch, Sebastian
Pecqueux, Mathieu
Kristiansen, Glen
Schneider, Martin
Hofmann, Bianca T.
Welsch, Thilo
Reissfelder, Christoph
Rahbari, Nuh N.
Fritzmann, Johannes
Brossart, Peter
Weitz, Jürgen
Feldmann, Georg
Kahlert, Christoph
Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
title Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
title_full Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
title_fullStr Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
title_full_unstemmed Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
title_short Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
title_sort inhibition of six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383957/
https://www.ncbi.nlm.nih.gov/pubmed/28388884
http://dx.doi.org/10.1186/s12885-017-3225-5
work_keys_str_mv AT lerbstristan inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT bishtsavita inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT scholchsebastian inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT pecqueuxmathieu inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT kristiansenglen inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT schneidermartin inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT hofmannbiancat inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT welschthilo inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT reissfelderchristoph inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT rahbarinuhn inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT fritzmannjohannes inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT brossartpeter inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT weitzjurgen inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT feldmanngeorg inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer
AT kahlertchristoph inhibitionofsix1affectstumourinvasionandtheexpressionofcancerstemcellmarkersinpancreaticcancer